Emerging Therapeutic Targets and Drug Delivery Approaches in IBD (Volume 101) (Advances in Pharmacology, Volume 101)
Original price was: $369.92.$217.60Current price is: $217.60.
Emerging Therapeutic Targets and Drug Delivery Approaches in IBD (Volume 101) (Advances in Pharmacology, Volume 101) | 9780443313585, Florin, Selaru
Author: Selaru, Florin
Edition: 1
ISBN: 9780443313585
Release Date: 27-11-2024
Package Dimensions: 9.3 x 6.3 x 0.9 inches
Languages: English
Binding: hardcover
Number Of Pages: 348
Details: Emerging Therapeutic Targets and Drug Delivery Approaches in IBD, Volume 101 in this ongoing series, highlights new advances, with this volume presenting interesting chapters on timely topics, including Fibrosis in IBD – AXL as a Promising Therapeutic Target, Developing a pathway to test anti-fibrotic drugs in Crohn’s disease, Emerging therapeutics for the management of intestinal fibrosis and strictures, GCPII for IBD, Fistulas/stem cell products for IBD/Crohn’s, The landscape of new therapeutic opportunities for IBD, TL1A : A Model For The Use Of Precision Medicine For The Treatment of Crohn’s Disease and Ulcerative Colitis, Dectin-1 as a therapeutic target for IBD, and more.
Additional sections cover BRD4 as an Emerging Epigenetic Therapeutic Target for Inflammatory Bowel Diseases, Scripps – S1P, The potential of targeting TREM-1 in Inflammatory Bowel Disease, and Microbiome therapies. Provides the latest information on emerging therapeutic targets and drug research Offers outstanding and original reviews on a range of emerging therapeutic targets and drug research topics Serves as an indispensable reference for researchers and students alike
User Reviews
Be the first to review “Emerging Therapeutic Targets and Drug Delivery Approaches in IBD (Volume 101) (Advances in Pharmacology, Volume 101)”
Vendor Information
- Store Name: Adobooks Marketplace
- Vendor: Adobooks Marketplace
- No ratings found yet!
Product Enquiry
Original price was: $369.92.$217.60Current price is: $217.60.


There are no reviews yet.